0000769993-15-001055.txt : 20151211
0000769993-15-001055.hdr.sgml : 20151211
20151211202348
ACCESSION NUMBER: 0000769993-15-001055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151209
FILED AS OF DATE: 20151211
DATE AS OF CHANGE: 20151211
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: T2 Biosystems, Inc.
CENTRAL INDEX KEY: 0001492674
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 204827488
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-457-1200
MAIL ADDRESS:
STREET 1: 101 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CARELLA THOMAS J.
CENTRAL INDEX KEY: 0001477767
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36571
FILM NUMBER: 151284414
MAIL ADDRESS:
STREET 1: C/O GOLDMAN, SACHS & CO.
STREET 2: 85 BROAD STREET
CITY: NEW YORK
STATE: NY
ZIP: 10004
4
1
ownershipdoc12082015101233.xml
X0306
4
2015-12-09-05:00
false
0001492674
T2 Biosystems, Inc.
TTOO
0001477767
CARELLA THOMAS J.
C/O GOLDMAN, SACHS & CO.
200 WEST STREET
NEW YORK
NY
10282
true
false
false
false
Common Stock
2015-12-09-05:00
4
P
false
700000
9.75
A
4157240
I
See footnotes
Stock options (Right to buy)
18.59
2025-06-19-04:00
Common Stock
17647
17647
I
See footnotes
The Reporting Person is a managing director of Goldman, Sachs & Co. ("Goldman Sachs"). Goldman Sachs is a wholly owned subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
In connection with the closing of a follow-on public offering (the "Offering") of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. which occurred on December 9, 2015, certain investment entities (the "GS Funds"), purchased an aggregate of 700,000 shares of Common Stock at the Offering price of $9.75 per share of Common Stock.
GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by certain of the GS Funds because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs is a wholly owned subsidiary of GS Group. Goldman Sachs is the investment manager of certain of the GS Funds.
The stock options vest and become exercisable in 12 substantially equal monthly installments commencing June 19, 2015. The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.
/s/ Yvette Kosic, Attorney-in-fact
2015-12-11-05:00